The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial

American Heart Journal

Volumn 189, Issue , 2017, Pages 68-74

  Holmes, David R ^a   Reddy, Vivek Y ^b   Buchbinder, Maurice ^c   Stein, Kenneth ^d   Elletson, Myriah ^d   Bergmann, Martin W ^e   Schmidt, Boris ^f   Saw, Jacqueline ^g  

^a MAYO CLINIC   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

^d BOSTON SCIENTIFIC CORPORATION   (United States)

^e Department of Psychiatry and Psychotherapy   (Germany)

^f CARDIOANGIOLOGISCHES CENTRUM BETHANIEN   (Germany)

^g VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BLEEDING TENDENCY; BLOOD CLOTTING TIME; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CHADS2 SCORE; CLINICAL EFFECTIVENESS; DIGESTIVE SYSTEM INJURY; DUAL ANTIPLATELET THERAPY; EMBOLISM; ENDOVASCULAR SURGERY; EPISTAXIS; FALLING; FLUOROSCOPY; HOSPITAL DISCHARGE; HUMAN; LEFT ATRIAL APPENDAGE CLOSURE DEVICE; OPEN HEART SURGERY; PATIENT SAFETY; PATIENT SELECTION; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; SEVERE RENAL IMPAIRMENT; STUDY DESIGN; SUBDURAL HEMATOMA; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSIENT ISCHEMIC ATTACK; VISUAL ANALOG SCALE; CLINICAL TRIAL; COMPLICATION; CONTRAINDICATIONS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART ATRIUM APPENDAGE; HEART SURGERY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PROCEDURES; PROSTHESES AND ORTHOSES; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; CARDIAC SURGICAL PROCEDURES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTHESES AND IMPLANTS; PROSTHESIS DESIGN; STROKE; TREATMENT OUTCOME;

EID: 85018788494     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2017.03.007     Document Type: Article

References (18)

1. 1. Colilla, S., Crow, A., Petkun, W., et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 112:8 (2013), 1142–1147.
2. 2. Wolf, P.A., Abbott, R.D., Kannel, W.B., Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:8 (1991), 983–988.
3. 3. Wolf, P.A., D'Agostino, R.B., Belanger, A.J., et al. Probability of stroke: a risk profile from the Framingham Study. Stroke 22:3 (1991), 312–318.
4. 4. Lamassa, M., Di Carlo, A., Pracucci, G., et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 32:2 (2001), 392–398.
5. 5. Ruff, C.T., Giugliano, R.P., Braunwald, E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:9921 (2014), 955–962.
6. 6. Granger, C.B., Alexander, J.H., McMurray, J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:11 (2011), 981–992.
7. 7. Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:10 (2011), 883–891.
8. 8. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:12 (2009), 1139–1151.
9. 9. Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:22 (2013), 2093–2104.
10. 10. Holmes, D.R., Reddy, V.Y., Turi, Z.G., et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 374:9689 (2009), 534–542.
11. 11. Holmes, D.R. Jr., Kar, S., Price, M.J., et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 64:1 (2014), 1–12.
12. 12. Camm, A.J., Accetta, G., Ambrosio, G., et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart, 2016.
13. 13. Boersma, L.V., Schmidt, B., Betts, T.R., et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J 37:31 (2016), 2465–2474.
14. 14. Saw, J., Lempereur, M., Percutaneous left atrial appendage closure: procedural techniques and outcomes. JACC Cardiovasc Interv 7:11 (2014), 1205–1220.
15. 15. Blackshear, J.L., Odell, J.A., Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 61:2 (1996), 755–759.
16. 16. Reddy, V.Y., Holmes, D., Doshi, S.K., et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 123:4 (2011), 417–424.
17. 17. Reddy, V.Y., Mobius-Winkler, S., Miller, M.A., et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study with Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 61:25 (2013), 2551–2556.
18. 18. Sharma, D., Reddy, V.Y., Sandri, M., et al. Left atrial appendage closure in patients with contraindications to oral anticoagulation. J Am Coll Cardiol 67:18 (2016), 2190–2192.